Baxter(US:BAX) Prnewswire·2025-11-03 15:10Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device malfunctions, which have reportedly caused serious risks to patients [2][4]. Group 1: Allegations and Impact - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that led to malfunctions, including underinfusion and overinfusion, posing risks of serious injury or death to patients [4]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to a heightened risk of customers removing the Novum LVPs from service and pausing new sales [4]. - Following the announcement on July 31, 2025, regarding the voluntary pause of shipments and installations of the Novum LVP, Baxter's stock price fell by 22.4%, closing at $21.76 [5]. Group 2: Legal Proceedings - Investors who suffered losses exceeding $100,000 in Baxter between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][2]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Baxter is December 15, 2025 [2][6]. - Faruqi & Faruqi is also inviting anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to come forward [6].